Skip to main content
. Author manuscript; available in PMC: 2013 Aug 29.
Published in final edited form as: Invest New Drugs. 2011 Jan 18;30(4):1709–1714. doi: 10.1007/s10637-011-9635-3

Table 2.

IC50 (μM) of 2-aryl-naphtho[2,3-d]oxazole-4,9-dione derivatives (8–12) on LNCaP prostate cancer cell line after 72 and 120 h exposure

Compd 72 h Exposure 120 h Exposure
8 1.0±0.08 0.19±0.025
9 0.035±0.005 0.40±0.056
10 0.1±0.01 0.03±0.006
11 0.5±0.065 0.01±0.002
12 0.03±0.004 0.06±0.005